Type 2 diabetes
Conditions
Interventions
once-daily SGLT2 inhibitor (dapagliflozin 5mg) as add-on to the conventional treatment
low-carbo (40-45%) diet as add-on to the conventional treatment
only conventional treatment (control)
for one wee
Sponsors
Fujita Yoshihito
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Type 2 diabetes without the history of taking any SGLT2 inhibitors in recent three months, age between 20 and 80 years, and BMI>20
Exclusion criteria
Exclusion criteria: Type 1 diabetes, secondary diabetes, severe ketosis, diabetic coma or pre-coma patients, alcoholism, severe depression or other psychological condition, malignancy, viral hepatitis, severe liver dysfunction, abnormal hemoglobinemia, severe infections diseases, pre- or post-surger, severe traumatic injury, contraindication for MRI like having metal pieces embedded in the body, pregnant or lactating woman, renal deficiency(eGFR<45mL/min/1.73m2), history of hypersensitivity to dapagliflozin, and those who are not considered to be suitable by an attending physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hepatocellular adenosine triphosphate (ATP) concentrations | — |
Secondary
| Measure | Time frame |
|---|---|
| Hepatocellular inorganic phosphate, phosphomonoesters (PME), hepatic lipid volume fraction identified by 31P MRS, and metabolic markers identified by metabolomic analysis | — |
Contacts
Public ContactKaori Ikeda
Kyoto University Hospital
Outcome results
None listed